AtaiBeckley Inc. (ATAI)
| Market Cap | 2.73B +160.1% |
| Revenue (ttm) | 4.47M +93.7% |
| Net Income | -668.19M |
| EPS | -2.14 |
| Shares Out | 370.86M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 9,587,449 |
| Open | 7.31 |
| Previous Close | 7.29 |
| Day's Range | 7.30 - 7.37 |
| 52-Week Range | 3.27 - 7.45 |
| Beta | 1.55 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 11, 2026 |
About ATAI
AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments. The company develops rapid-acting and durable therapies for conditions with limited treatment options. Its pipeline includes BPL-003 (mebufotenin benzoate), an intranasal formulation in Phase 2 and 3 clinical studies for treatment-resistant depression and alcohol use disorder; ELE-101, a serotonergic psychedelic for major depressive disorder; and RL-007, an orally bioavailable pro-cognitive neuro... [Read more]
Financial Performance
In 2025, AtaiBeckley's revenue was $4.09 million, an increase of 1227.60% compared to the previous year's $308,000. Losses were -$660.05 million, 342.2% more than in 2024.
Financial StatementsNews
AtaiBeckley Transcript: EGM 2026
Shareholders approved the merger agreement with Eli Lilly and Company and Albali Acquisition Corporation. Both proposals on the agenda passed, with final vote results to be published within four business days.
AtaiBeckley Quarterly report: Q2 2026
AtaiBeckley has published its Q2 2026 quarterly earnings report on August 11, 2026.
AtaiBeckley Proxy statement: Proxy filing
AtaiBeckley filed a proxy statement on August 10, 2026, providing details for shareholder voting and corporate governance matters.
AtaiBeckley Proxy statement: Proxy filing
AtaiBeckley filed a proxy statement on July 30, 2026, providing details for shareholder voting and corporate governance matters.
The market for psychedelic drugs to treat mental health conditions gets a big buy signal
Thursday's announcement that Eli Lilly will acquire AtaiBeckley, a clinical-stage maker of psychedelic drugs, for up to $3.8 billion indicates Big Pharma's increasing embrace of a long-stigmatized cla...
AtaiBeckley stock is soaring, and it has Eli Lilly to thank
AtaiBeckley (ATAI) shares are ripping higher on Thursday morning after pharmaceutical giant Eli Lilly (LLY) said it will acquire the clinical-stage biotechnology firm for up to $3.8 billion. Lilly has...
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AtaiBeckley Inc. (Nasdaq – ATAI), Distribution Solutions Group, Inc. (Nasdaq – DSGR), Cross Country Healthcare, Inc. (Nasdaq – CCRN), Nuvalent, Inc. (Nasdaq – NUVL)
BALA CYNWYD, Pa., July 16, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (j...
Lilly Buys Psychedelic Drugmaker AtaiBeckley for $3.8 Billion
Eli Lilly & Co. agreed to buy AtaiBeckley Inc. for as much as $3.8 billion, underscoring growing interest from large drugmakers in psychedelic medicine. Madison Muller has more on "Bloomberg Open Inte...
AtaiBeckley Proxy statement: Proxy filing
AtaiBeckley filed a proxy statement on July 16, 2026, providing details for shareholder voting and corporate governance matters.
AtaiBeckley Proxy statement: Proxy filing
AtaiBeckley filed a proxy statement on July 16, 2026, providing details for shareholder voting and corporate governance matters.
AtaiBeckley Proxy statement: Proxy filing
AtaiBeckley filed a proxy statement on July 16, 2026, providing details for shareholder voting and corporate governance matters.
AtaiBeckley Proxy statement: Proxy filing
AtaiBeckley filed a proxy statement on July 16, 2026, providing details for shareholder voting and corporate governance matters.
AtaiBeckley Proxy statement: Proxy filing
AtaiBeckley filed a proxy statement on July 16, 2026, providing details for shareholder voting and corporate governance matters.
AtaiBeckley Proxy statement: Proxy filing
AtaiBeckley filed a proxy statement on July 16, 2026, providing details for shareholder voting and corporate governance matters.
AtaiBeckley Proxy statement: Proxy filing
AtaiBeckley filed a proxy statement on July 16, 2026, providing details for shareholder voting and corporate governance matters.
AtaiBeckley Proxy statement: Proxy filing
AtaiBeckley filed a proxy statement on July 16, 2026, providing details for shareholder voting and corporate governance matters.
AtaiBeckley Proxy statement: Proxy filing
AtaiBeckley filed a proxy statement on July 16, 2026, providing details for shareholder voting and corporate governance matters.
AtaiBeckley Proxy statement: Proxy filing
AtaiBeckley filed a proxy statement on July 16, 2026, providing details for shareholder voting and corporate governance matters.
Eli Lilly to Buy AtaiBeckley for Initial $2.8 Billion
Eli Lilly has struck a deal to buy mental-health-focused AtaiBeckley for an initial $2.8 billion, continuing the drugmaker's recent buying spree.
Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley deal
Eli Lilly said on Thursday it would acquire psychedelic drug developer AtaiBeckley for up to $3.8 billion, entering the race to develop psychedelic treatments for depression and other ment...
Eli Lilly to buy psychedelics maker AtaiBeckley for $2.8 billion as experimental treatments gain traction
Eli Lilly will acquire psychedelic drugmaker AtaiBeckley for $2.8 billion. AtaiBeckley is developing several psychedelics for mental health conditions.
Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions
AtaiBeckley's lead program, BPL-003, is designed to provide durable relief from treatment-resistant depression Acquisition expands Lilly's neuroscience pipeline to address some of the most challenging...
AtaiBeckley surges after report Lilly poised to buy psychedelic drug developer
AtaiBeckley shares soared 50% premarket on Thursday after a report that Eli Lilly was in talks to acquire the psychedelic drug developer as soon as this week.
This Psychedelic Pharma Stock Is Soaring 50% on Report of Eli Lilly Takeover Talks
Eli Lilly is in talks to buy a psychedelic drugmaker at a premium, according to a report.
Eli Lilly nears deal to buy psychedelic drugmaker AtaiBeckley, Bloomberg News reports
Eli Lilly is in talks to acquire psychedelic drugmaker AtaiBeckley , and a deal could be announced as soon as this week, Bloomberg News reported on Wednesday, citing people familiar with th...